title: A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
abstract: Human papillomavirus infection causes cervical cancer, a significant portion of anal, genital and oropharyngeal cancers, genital warts and recurrent respiratory papillomatosis. In June 2006, a quadrivalent human papillomavirus-6/11/16/18 vaccine (GARDASIL/SILGARD®; Merck, NJ, USA) was licensed in the USA; subsequent approval has been granted in the EU (September 2006). It has since been approved in 121 countries with over 74 million doses distributed globally as of March 2011.
authors.affiliation: Mount Sinai School of Medicine, 420 West 23rd Sreet, New York, NY, USA. segmd@prodigy.net
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Goldstone
authors.forename: Scott
authors.initials: S
authors.lastname: Vuocolo
mesh_terms: D003218:Condylomata Acuminata / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D017277:Drug Approval; D005062:European Union; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D008297:Male; D009959:Oropharyngeal Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D010212:Papilloma / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000150:complications* / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination / Q000379:methods
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines